3 Reasons Why Executives are Using a Medical Device to Manage Mental Health Fisher Wallace Laboratories is challenging our reliance on drug therapy to treat anxiety, insomnia, and depression.

If the C-Suite doesn't realize their own mental health and that of their team's is a top priority, long-term performance is doomed. Put another way, it's foolhardy to demand long hours and high performance without also supporting brain function. So how are executives managing mental health in the (post) COVID-19 world?

Fisher Wallace Laboratories was recently named one of "5 Health-Tech Startups to Watch in 2021." In the article, the journalist writes: "The Fisher Wallace stimulator has shown promise in clinical trials for treating depression, anxiety, and insomnia. One 20-minute treatment activates key neurotransmitters, including dopamine, beta-endorphin and serotonin, and lowers the stress hormone cortisol."

In the world of FDA-regulated medical devices, with its long research and regulatory timelines, a ten-year old company is still considered a startup. Fisher Wallace Laboratories has succeeded over the past decade by making its mental health treatment device affordable out-of-pocket (avoiding the insurance reimbursement quagmire) and easy-to-use without causing any serious side effects. In doing so, it has won over 60,000 patients and 10,000 prescribers. Over the past 9 months, Fisher Wallace has also raised over $2.3 million through its equity crowdfunding campaign on StartEngine.

Following are 3 reasons why top executives are turning to Fisher Wallace to manage their own mental health needs, as well as the needs of their teams.

1. The Fisher Wallace device is cleared by the FDA and has been proven to be safe and effective in multiple clinical trials.

Fisher Wallace is not a wellness startup - it's a medical startup. The wellness market - whether supplements, gadgets, meditation, or therapy apps - typically make a lot of promises without providing much scientific evidence or submitting to intense FDA regulation. Not the case with Fisher Wallace - Fisher Wallace has invested in large-scale clinical trials, including three conducted during the pandemic, and has been regulated by the FDA for over a decade. The company's device works by stimulating neurotransmitter production while lowering cortisol and modulating the brain's default mode network. By electrically (and comfortably) stimulating the brain to improve function, the device avoids the side effects caused by ingested medications.

2. The Fisher Wallace device is affordable out-of-pocket and is shipped directly to the customer's door following a simple telemedicine process (no video or phone call with a doctor required).

By applying consumer electronics manufacturing efficiencies to medical device production and eliminating third party markups, Fisher Wallace is able to make its products available to the public at affordable out-of-pocket prices - its flagship device retails for $499. They then drop-ship the device via FedEx to the customer's door following a brief telemedicine process that takes less than 60 seconds to complete.

3. It's extremely easy-to-use.

The Fisher Wallace device is easier to use than a TV remote control. That's important for ensuring that customers use it correctly from the very first use - and to ensure that usage is easily repeatable. The company is now developing a Version 2 device, designed by superstar industrial designer Eric Fields (Beats, Nest) that will look and feel like a device produced by the world's leading consumer hardware companies.

Click here to learn more about Fisher Wallace's equity crowdfunding campaign on StartEngine. Investors receive a free Fisher Wallace device with a $1500 investment.

This Reg A+ offering is made available through StartEngine Primary, LLC. It is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please review the offering circular before investing.